Patents by Inventor David Lonergan

David Lonergan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF
    Publication number: 20230382891
    Abstract: Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of QPCTL activity.
    Type: Application
    Filed: October 19, 2021
    Publication date: November 30, 2023
    Inventors: Min TENG, David T. PUERTA, Baskar NAMMALWAR, Christian PEREZ, David LONERGAN, David Pifer MARTIN
  • Autotaxin inhibitor compounds
    Patent number: 11779568
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: October 10, 2023
    Assignee: Sabre Therapeutics LLC
    Inventors: John Howard Hutchinson, David Lonergan
  • Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
    Patent number: 11459309
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: October 4, 2022
    Assignee: PHARMAKEA, INC.
    Inventors: David Lonergan, Kevin Ross Holme, Martin W. Rowbottom
  • AUTOTAXIN INHIBITOR COMPOUNDS
    Publication number: 20220265608
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: John Howard Hutchinson, David Lonergan
  • Lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 11358936
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 14, 2022
    Assignee: PharmAkea, Inc.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
  • Autotaxin inhibitor compounds
    Patent number: 11344533
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: May 31, 2022
    Assignee: Sabre Therapeutics LLC
    Inventors: John Howard Hutchinson, David Lonergan
  • LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
    Publication number: 20210171465
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: July 17, 2020
    Publication date: June 10, 2021
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON, David LONERGAN
  • CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING
    Publication number: 20200361901
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventors: David LONERGAN, Kevin Ross HOLME, Martin W. ROWBOTTOM
  • Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
    Patent number: 10774069
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: September 15, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: David Lonergan, Kevin Ross Holme, Martin W. Rowbottom
  • Lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 10766860
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: September 8, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
  • AUTOTAXIN INHIBITOR COMPOUNDS
    Publication number: 20200268713
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 27, 2020
    Inventors: John Howard HUTCHINSON, David LONERGAN
  • AUTOTAXIN INHIBITORS AND USES THEREOF
    Publication number: 20200215034
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: Gretchen BAIN, Jillian Frances EVANS, John Howard HUTCHINSON, David LONERGAN
  • Autotaxin inhibitor compounds
    Patent number: 10688081
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 23, 2020
    Assignee: SABRE THERAPEUTICS LLC
    Inventors: John Howard Hutchinson, David Lonergan
  • Autotaxin inhibitors and uses thereof
    Patent number: 10632104
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: April 28, 2020
    Assignee: SABRE THERAPEUTICS LLC
    Inventors: Gretchen Bain, Jillian Frances Evans, John Howard Hutchinson, David Lonergan
  • CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING
    Publication number: 20190202805
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: September 6, 2017
    Publication date: July 4, 2019
    Inventors: David LONERGAN, Kevin Ross HOLME, Martin W. ROWBOTTOM
  • AUTOTAXIN INHIBITOR COMPOUNDS
    Publication number: 20180243267
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: John Howard HUTCHINSON, David LONERGAN
  • Autotaxin inhibitor compounds
    Patent number: 9999615
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 19, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan
  • TETRACYCLIC AUTOTAXIN INHIBITORS
    Publication number: 20180162859
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Inventors: John Howard Hutchinson, David Lonergan, Martin Rowbottom, Andiliy Gokching Lai
  • AUTOTAXIN INHIBITORS AND USES THEREOF
    Publication number: 20180147185
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Application
    Filed: May 24, 2016
    Publication date: May 31, 2018
    Applicant: PharmAkea, Inc.
    Inventors: Gretchen BAIN, Jillian Frances EVANS, John Howard HUTCHINSON, David LONERGAN
  • Heterocyclic vinyl autotaxin inhibitor compounds
    Patent number: 9951026
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 24, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, Timothy Andrew Parr, Kevin Duane Bunker, David Lonergan